Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02501161 · ClinicalTrials.gov registry record · Phase 3
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,012
- Enrollment target
NCT02501161 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,012 participants.
The verdict
NCT02501161, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,012 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve subjects with type 2 diabetes mellitus inadequately controlled with oral anti diabetics.
Interventions
- DRUG insulin glargine
- DRUG insulin degludec/liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,012 participants |
| Start Date | 2016-01-31 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02501161
The ClinicalTrials.gov registry entry for NCT02501161 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,012 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT02501161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02501161 about?
NCT02501161 is a clinical study titled "A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus". This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve subjects with type 2 diabetes mellitus inadequately controlled with oral...
What is the current status of trial NCT02501161?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,012 participants. The study started on 2016-01-31. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT02501161?
The interventions under investigation include: insulin glargine (DRUG), insulin degludec/liraglutide (DRUG).
Who is sponsoring clinical trial NCT02501161?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.